Investigators from the University of Manchester, Manchester, UK recently demonstrated a significant interaction between volume of identified calcifications and their mean radiotherapy (RT) dose in predicting survival in patients with non-small-cell lung cancer (NSCLC).
Age ≥60 years and ≥20 percent of normal lung volume receiving a radiation dose of ≥20 Gy (V20) are significant predictors of radiation pneumonitis (RP) in patients treated with intensity-modulated radiotherapy (IMRT) for lung cancer, a Chinese study has shown.
Reduction in gross tumour volume (GTV) during concurrent chemoradiation therapy (CRT) may be linked to worse overall survival (OS) in patients with locally advanced lung adenocarcinoma, according to a recent study reported at the International Association for the Study of Lung Cancer (IASLC) 19th World Conference on Lung Cancer (WCLC 2018).
Prognostic nutrition index (PNI) strongly predicts clinical outcomes in patients with locally advanced non-small-cell lung cancer (NSCLC), according to two studies presented at the International Association for the Study of Lung Cancer 19th World Conference on Lung Cancer (WCLC 2018).
An updated 10-year analysis of the RTOG 0214 trial showed that the use of prophylactic cranial irradiation (PCI) improved disease-free survival (DFS) and reduced brain metastases, but failed to improve overall survival (OS) in patients with locally advanced non-small-cell lung carcinoma (LA-NSCLC).
Adding nintedanib to standard-of-care pemetrexed-cisplatin doublet chemotherapy does not improve progression-free survival (PFS) in patients with malignant pleural mesothelioma (MPM), the phase III LUME-Meso study has shown.
The anaplastic lymphoma kinase (ALK) inhibitor brigatinib demonstrated better progression-free survival (PFS) vs crizotinib among ALK-positive non-small-cell lung cancer (NSCLC) patients not previously treated with an ALK inhibitor.
Adaptive radiotherapy (RT) guided by 18F-FDG PET/CT functional imaging improves objective response rate (ORR) and survival in non-small-cell lung cancer (NSCLC) without increasing toxicity compared with conventional RT, a small study conducted in China has shown.
Adding cetuximab to afatinib does not improve overall survival (OS), progression-free survival (PFS) or objective response rate (ORR) in the first-line treatment of patients with advanced or recurrent non-small-cell lung cancer (NSCLC) harbouring classical sensitizing EGFR mutations.
Atezolizumab, when added to standard-of-care chemotherapy, significantly improves survival of patients with extensive-stage small-cell lung cancer (SCLC) in the first-line setting, according to results of the IMpower133 trial reported at the International Association for the Study of Lung Cancer (IASLC) 19th World Conference on Lung Cancer (WCLC 2018).
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
The selective serotonin reuptake inhibitor escitalopram holds promise in the prevention of Alzheimer’s disease, reducing amyloid-β-42 levels in cerebrospinal fluid and brain tissue in older adults with normal cognitive function, according to recent evidence.
Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.